Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ11961199-0,42
KB10481051-0,10
PKN7271,45-1,79
Msft-1,22
Nokia4,5754,7751,01
IBM-2,28
Mercedes-Benz Group AG53,1653,17-0,04
PFE-2,04
22.05.2025 9:03:00
Indexy online
AD Index online
select
AD Index online
 

  • 21.05.2025
Myriad Genetics (MYGN.O, NASDAQ Cons)
Závěr k 21.5.2025 Změna (%) Změna (USD) Objem obchodů (ks)
4,07 -8,54 -0,38 2 153 277
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 22.05.2025
Popis společnosti
Obecné informace
Název společnostiMyriad Genetics Inc
TickerMYGN
Kmenové akcie:Ordinary Shares
RICMYGN.O
ISIN-
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.03.2025
Počet zaměstnanců k 31.12.2024 2 700
Akcie v oběhu k 02.05.2025 92 177 383
MěnaUSD
Konstituent indexůS&P 600 Small Cap
Kontaktní informace
Ulice322 North 2200 West
MěstoSALT LAKE CITY
PSČ84116
ZeměUnited States
Kontatní osobaMatt Scalo
Funkce kontaktní osobyInvestor Relations
Telefon18 015 843 600
Fax18015843640
Kontatní telefon18 015 843 532

Business Summary: Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Myriad Genetics Inc revenues decreased 3% to $195.9M. Net loss decreased 100% to $100K. Revenues reflect Rest of world segment decrease of 25% to $14.3M, United States segment decrease of 1% to $181.6M.
Odvětvová klasifikace
TRBC2012Laboratory Diagnostic & Testing Substances
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSIn-Vitro Diagnostic Substance Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICSTesting Laboratories and Services
NAICS2007In-Vitro Diagnostic Substance Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007Testing Laboratories
NAICS1997InVitro Diagnostic Substance Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Testing Laboratories
SICDiagnostic Substances
SICDiagnostic Substances
SICCommercial Physical Research
SICTesting Laboratories



  • Poslední aktualizace: 22.05.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorSamraat Raha5230.04.202511.12.2023
Chief Financial OfficerScott Leffler5029.01.202429.01.2024
Chief Operating Officer and Chief Commercial OfficerMark Verratti5630.04.202501.08.2017
Chief People OfficerShereen Solaiman52
Senior Vice President, Chief of StaffMargaret Ancona5518.02.2021
Chief Technology OfficerKevin Haas4018.02.202118.02.2021
Chief Scientific OfficerDale Muzzey45
Chief Commercial OfficerBrian Donnelly-01.05.202501.05.2025
Chief Legal OfficerJennifer Fox5203.09.202403.09.2024